Abstract:Background: Higher visit-to-visit variability in fasting glucose (GV) and HbA1c (A1cV), indicating worse glycemic control, is associated with incident dementia in adults with type 2 diabetes (T2D). Few studies have investigated the relationship of GV and A1cV with cognitive decline in the general population. Hypothesis: Higher visit-to-visit GV and A1cV are associated with decline in global cognitive performance. Methods: Fasting glucose (FG) was measured in MESA participants at Exam 1 (2000-02) and each of 5 follow-up exams, and HbA1c was measured at Exam 2 (2002-04), Exam 5 (2010-12), and Exam 6 (2016-18). Global cognitive performance was assessed by the Cognitive Abilities Screening Instrument (CASI; scored 0-100) at Exam 5 and re-administered to a subset at Exam 6. We calculated GV and A1cV as the SD (SD GV ; SD A1c ), coefficient of variation (CV GV ; CV A1c ), and average real variability (ARV GV ; ARV A1c ), and defined global cognitive decline as a ≥1 race/ethnicity-specific SD decrease in CASI score from Exam 5 to Exam 6 (-5.9 to -8.2 points across 4 races/ethnicities). We report the CASI point-change and relative odds of decline (OR) from Exam 5 to Exam 6 (95% CI) associated with continuous log 2 -normalized and highest quartile (Q4 vs. quartiles 1-3 for potential floor effects) of GV and A1cV from inverse probability of censor-weighted linear and logistic regression adjusted for Exam 5 CASI score, age, sex, race/ethnicity, education, vascular risk factors, and APOE ε4 status. Results: A total of 1834 Exam 6 participants (aged 73±8 years; 47% men; 43% White; 7% with T2D at Exam 1; 13% with incident T2D over follow-up) had ≥3 FG measurements and repeat CASI data. The overall 6-year mean (SD) change in CASI was +0.1 (6.6) points. Q4 of SD GV , CV GV , and ARV GV was associated with 0.8 (0.1, 1.5), 0.9 (0.2, 1.6), and 0.7 (0.03, 1.4) point decreases in CASI, respectively, and Q4 of CV GV was associated with higher odds of global cognitive decline (OR = 1.5 [1.1, 2.1]); continuous GV indices were not associated with CASI change. Associations with SD GV and CV GV were driven by participants with incident T2D (interaction P <0.01 for change and odds of decline). In 1175 participants with 3 HbA1c measurements, a 2-fold increment in ARV A1c was associated with a 0.5 (0.1, 0.9) point decrease in CASI. However, in participants with incident T2D, 2-fold increments in SD A1c , CV A1c , and ARV A1c were associated with 1.3 (0.2, 2.4), 1.4 (0.2, 2.6), and 1.8 (0.6, 3.0) point decreases in CASI, respectively, and a 2-fold increment in ARV A1c was associated with greater odds of decline (OR = 2.1 [1.1, 3.8]) (interaction P all <0.01). There were no associations with Q4 of A1cV indices. Associations did not differ by sex, race/ethnicity, or Exam 1 T2D status. Conclusions: Poor glycemic control over 14-16 years is associated with modest cognitive decline over the subsequent 6-8 years, particularly among adults at high risk for T2D during mid- to late-life.

Depressive Symptoms, Glial Fibrillary Acid Protein Concentrations, and Cognitive Decline in a Cohort Study

Demographic and Clinical Characteristics Associated With Serum GFAP Levels in an Ethnically Diverse Cohort

A population‐based meta‐analysis of circulating GFAP for cognition and dementia risk

Racial and ethnic differences in the association between depressive symptoms and cognitive outcomes in older adults: Findings from KHANDLE and STAR

Relationships among Serum C-reactive Protein, Receptor for Advanced Glycation Products, Metabolic Dysfunction, and Cognitive Impairments

Amyloid Burden and Depressive Symptom Trajectories in Older Adults at Risk of Developing Cognitive Decline

Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression

Perceived Stress, Blood Biomarkers, and Cognitive Functioning in Older Adults

From Blue to Gray: Inflammation and Neurodegeneration in Depression

Association of plasma biomarkers with cognition, cognitive decline, and daily function across and within neurodegenerative diseases: Results from the Ontario Neurodegenerative Disease Research Initiative

Synergistic effects of GFAP and Aβ42: Implications for white matter integrity and verbal memory across the cognitive spectrum

Associations of the Rate of Change in Geriatric Depression Scale with Amyloid and Cerebral Glucose Metabolism in Cognitively Normal Older Adults: A Longitudinal Study

Association of subjective memory complaints with serum biomarkers of neurodegeneration and cognition: A population‐based study

Longitudinal correlation of cerebrospinal fluid GFAP and the progression of cognition decline in different clinical subtypes of Parkinson's disease

Abstract 063: Higher Visit-to-Visit Variability in Fasting Glucose and HbA1c is Associated with Decline in Global Cognitive Performance: The Multi-Ethnic Study of Atherosclerosis (MESA)

Association Between Longitudinal Increases in Serum Glucose and Metabolic Decline in Azheimer’s Disease-Related Brain Regions (P6.321)

Association of Presynaptic Loss with Alzheimer's Disease and Cognitive Decline.

Fibrillar Amyloid Correlates of Preclinical Cognitive Decline.

Prospective associations of interleukin-6 and APOE allele with cognitive decline in biracial community-dwelling older adults: The Chicago Health and Aging Project (CHAP)

Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease

Divergent Roles of Vascular Burden and Neurodegeneration in the Cognitive Decline of Geriatric Depression Patients and Mild Cognitive Impairment Patients